Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jiangsu Boli Bioproducts is a China-based industrial biotechnology company focused on the research, development, manufacturing, and sale of enzyme products. Its portfolio appears centered on commercial enzymes for food processing, starch sugar, alcohol and brewing, baking, protein hydrolysis, juice processing, animal feed, fuel ethanol, textiles, and agricultural applications rather than human therapeutics. The company highlights submerged fermentation, extraction, and refining capabilities, along with ISO 9001, ISO 14001, ISO 22000, FSSC 22000, and GMP-aligned manufacturing standards. Boli traces its origins to Wuxi Boli Bioproducts in 1998 and later expanded through Jiangsu and Shanghai entities, as well as a U.S. commercial presence. It also states that it operates a joint industrial enzyme R&D center with Jiangnan University and has built significant production capacity for enzyme manufacturing.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Boli.